Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-03

Clinical Trial Update: A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects [Phase 3]

View source ↗

Summary

A Phase 3 study of levalbuterol tartrate HFA inhalation aerosol in pediatric asthma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Levalbuterol Tartrate HFA Inhalation Aerosol MDI (levalbuterol tartrate)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Asthma | Phase 3 | Status: TERMINATED | Results posted: 2016-02-03